Title
Low income as a determinant of exercise capacity in COPD

Permalink
https://escholarship.org/uc/item/0jn3t3ff

Authors
Porta, Ana Sofia
Lam, Nyanjok
Novotny, Paul
et al.

Publication Date
2019

DOI
10.1177/1479972318809491

Peer reviewed
Low income as a determinant of exercise capacity in COPD

Ana Sofia Porta¹, Nyanjok Lam¹, Paul Novotny², Roberto Benzo¹* and the NETT Research Group

Abstract
Exercise capacity (EC) is a critical outcome in chronic obstructive lung disease (chronic obstructive pulmonary disease (COPD)). It measures the impact of the disease and the effect of specific interventions like pulmonary rehabilitation (PR). EC determines COPD prognosis and is associated with health-care utilization and quality of life. Field walking tests and cardiopulmonary exercise test (CPET) are two ways to measure EC. The 6-minute walking test (6MWT) is the commonest and easiest field test. CPET has the advantage of assessing maximal aerobic capacity. Determinants of EC include age, gender, breathlessness, and lung function. Previous research suggests that socioeconomic status (SES), a meaningful factor in COPD, may also be associated with EC. However, those findings have not been replicated. We aimed to determine whether SES is an independent factor associated with EC in COPD. For this analysis, we used the National Emphysema Treatment Trial (NETT) database. NETT was a multicenter clinical trial where severe COPD patients were randomized to lung volume reduction surgery or medical therapy. Patients self-reported their income and were divided in two groups whether it was less or above US$30,000. Patients with a lower income had worse results in 6MWT (p < 0.0001). We found an independent association between income and the 6MWT in patients with severe COPD after adjusting for age, gender, lung function, dyspnea, and living conditions (p < 0.0007). One previous publication stated the relationship between income and EC. Our research confirms and extends previous publications associating EC with income by studying a large and well characterized cohort of severe COPD patients, also addressing EC by two different methods (maximal watts and 6MWT). Our results highlight the importance of addressing social determinants of health such as income when assessing COPD patients.

Keywords
COPD, social determinants of health, exercise capacity, quality of life, pulmonary rehabilitation, CPET, 6-minute walking test

Introduction
Exercise capacity (EC) is a critical outcome in chronic obstructive lung disease (chronic obstructive pulmonary disease (COPD)).¹ It measures the impact of the disease and tests the effect of specific interventions.¹-³ EC determines COPD prognosis due to its relation with hospitalizations for exacerbations and all-cause mortality.⁴,⁵ Importantly, from a patient-centered focus, it is related to health-care utilization, quality of life (QoL), and symptoms.³

¹ Mindful Breathing Laboratory, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, MN, USA
² Health Sciences Research-Biomedical Statistics and Informatics, Mayo Clinic, MN, USA

Corresponding author:
Roberto Benzo, Mindful Breathing Laboratory, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Email: benzo.roberto@mayo.edu
Field walking tests and cardiopulmonary exercise test (CPET) are two ways to measure EC. Among those, the 6-minute walking test (6MWT) is the commonest and easiest.\(^1,2,6\) CPET has the advantage of assessing maximal aerobic capacity and contributes better to the differential diagnosis.\(^7\) EC determinants are many,\(^6,8\) including age, breathlessness, and lung function.

Socioeconomic status (SES), a meaningful factor in COPD related to QoL,\(^9\) physical activity,\(^10\) completion of pulmonary rehabilitation (PR), and all-cause mortality,\(^11\) may also predict EC. Recent data show that SES also influences EC, with lower income patients having poorer results\(^12\); however, that finding has never been replicated.

Our aim is to determine whether income is an independent factor associated with EC in COPD, which would raise its importance as a meaningful factor to be assessed.

### Methods

The present analysis used the National Emphysema Treatment Trial (NETT) database.\(^13\) This multicenter trial randomized severe COPD patients with no significant comorbidities to lung volume reduction surgery or medical therapy, after 6–10-week PR.\(^13,14\) Smoking cessation, biochemically validated, was required at least 6 months before randomization. Patients were divided in two groups whether their annual reported income was less or above US$30,000, a limit chosen following data of US census bureau and Pew Research center.\(^15,16\)

EC was measured by the 6MWT and maximal watts during CPET, following the American Thoracic Society Guidelines (ATS).\(^6,17\) Pulmonary function tests followed ATS.\(^15,19\)

Statistical analyses, associations between income and categorical variables, were tested between income groups using \(\chi^2\) tests. Associations between income level and continuous variables were tested between groups using Wilcoxon tests. The association between income and 6MWT as well as income and CPET was explored using linear models adjusted for marital status, loneliness, age, gender, FEV1% predicted, modified medical research council scale (MMRC), smoking pack years, and education. All analyses were tested with 5% type I error rates with no adjustments for multiple testing. Analyses were carried out using SAS version 9.4.

### Results

In total, 1218 patients completed PR and were analyzed using baseline data. Table 1 shows population’s characteristics and Tables 2 and 3 show the models designed to determine the independent association between income and EC.

The association between 6MWT and income (Table 2) remained significant after adjusting for meaningful confounders such as sex, age, Post BD FEV1% predicted, MMRC, marriage, loneliness, smoking pack years, and education (yes or no). We also found a significant association between income and maximal load in watts on CPET (Table 3) validating the 6MWT results. In addition, our results showed individuals with low income found themselves lonelier (Tables 1 and 2).

### Discussion

We found that low income is associated with worse results in the 6MWT after adjusting for meaningful confounders. The latter was further validated using another measure of EC: watts in CPET. Our findings confirm and extend a previous report\(^12\) but in a larger and more characterized cohort of severe COPD, using two different EC measures.

Given the 6MWT’s prognostic significance,\(^4-6\) our findings are important because usually income is not taken into account in COPD evaluation, despite being a factor that is easily obtainable, and conveys information about patients’ overall social condition. Plausible explanations for our results might include that financial constrains may limit patients’ access to programs like PR, as stated by previous publications.\(^21-23\) The fact of finding low-income participants more lonely suggests another social, yet critical repercussion of low income. Loneliness is independently related to poorer outcomes and higher health-care utilization in COPD (article in press).

### Limitations

Given that NETT selected severe emphysema COPD patients without significant comorbidities, our results may limit generalizability.
Table 1. Characteristics of all 1206 patients at baseline.

| Characteristics                        | Income ≥US$30,000 (N = 563) | Income ≤US$30,000 (N = 643) | p Value |
|----------------------------------------|-----------------------------|-----------------------------|---------|
| Medical treatment                      | 52.0%                       | 49.1%                       | 0.3153  |
| Sex, male                              | 65.4%                       | 57.5%                       | 0.0054  |
| Age, mean (SD) (years)                 | 67.2 (5.5)                  | 65.6 (6.6)                  | 0.0001  |
| Married                                | 83.3%                       | 48.5%                       | <0.0001 |
| Lonelyb                                | 5.5%                        | 10.1%                       | 0.0031  |
| Smoking pack years                    | 65.4 (29.3)                 | 63.6 (32.6)                 | 0.0826  |
| Post BD FEV1% pred, mean (SD)          | 26.8 (7.1)                  | 26.6 (7.2)                  | 0.3947  |
| 6MWD in feet, mean (SD)                | 1250.7 (314.8)              | 1171.7 (306.8)              | <0.0001 |
| Maximum load (watts), mean (SD)c       | 41.6 (22.7)                 | 36.8 (20.4)                 | 0.0001  |
| Total days in hospital, mean (SD)      | 3.0 (7.8)                   | 3.3 (7.6)                   | 0.3840  |
| Any days in hospital, yes              | 31.7%                       | 33.8%                       | 0.4620  |
| Total visits to ER, mean (SD)          | 0.6 (1.1)                   | 0.7 (1.3)                   | 0.5015  |
| Any visit to ER, yes                   | 37.5%                       | 39.7%                       | 0.4659  |
| Follow-up status, deadd                | 39.4%                       | 41.7%                       | 0.4278  |
| MRC Dyspnea Scale                      |                             |                             | 0.0058  |
| 0                                      | 1.4%                        | 1.6%                        |         |
| 1                                      | 0.2%                        | 0.5%                        |         |
| 2                                      | 29.2%                       | 22.1%                       |         |
| 3                                      | 23.5%                       | 19.9%                       |         |
| 4                                      | 45.7%                       | 55.9%                       |         |
| Education beyond high schoolb          | 62.9%                       | 35.1%                       | <0.0001 |

N: sample; SD: standard deviation; Post BD FEV1% pred: postbronchodilator forced expiratory volume in 1 second % predicted; ER: emergency department; MRC scale: Medical Research Council Dyspnea Scale; 6MWD: 6-minute walk distance. Every value in italics <0.05 denotes significance (standard practice).

abLoneliness and isolation was measured by asking subjects “Do you feel lonely or socially isolated now or in the last 3 days?” An answer was either “yes” or “no.”

cMaximum load (watts) was chosen to measure exercise capacity during CPET.

dThe follow-up period was 2 years.

Table 2. Income as a determinant of 6MWT, adjusted for age, sex, Post FEV1% predicted, MMRC, loneliness, married status, smoking pack years, and education beyond high school.

| Variables                             | DF | Parameter Estimates | Standard error | t Value | Pr > |t| |
|---------------------------------------|----|---------------------|----------------|---------|-------|-------|
| Intercept                             | 1  | 1607.40             | 95.58          | 16.82   | <0.0001 |
| Married                               | 1  | 27.47               | 18.45          | 1.49    | 0.1367 |
| Lonely or Isolateda                   | 1  | -23.24              | 29.50          | -0.79   | 0.4310 |
| Income < US$30,000                    | 1  | -48.15              | 17.76          | -2.71   | 0.0068 |
| Age                                   | 1  | -10.87              | 1.35           | -8.05   | <0.0001 |
| Sex, male                             | 1  | 180.85              | 17.82          | 10.15   | <0.0001 |
| Post BD FEV1% pred                    | 1  | 16.10               | 1.17           | 13.75   | <0.0001 |
| MMRC                                  | 1  | -67.59              | 8.61           | -7.85   | <0.0001 |
| Education beyond high schoolb         | 1  | 32.89               | 16.78          | 1.96    | 0.0502 |
| Smoking pack years                   | 1  | -0.11               | 0.26           | -0.42   | 0.6720 |

DF: degrees of freedom; Pr > |t|: t-test significance level; Post BD FEV1% pred: post bronchodilator forced expiratory volume in 1 second; MMRC: Modified medical research council scale. Every value in italics <0.05 denotes significance (standard practice).

aLoneliness and isolation was measured by asking subjects “Do you feel lonely or socially isolated now or in the last 3 days?” An answer was either “yes” or “no.”

bEducation was determined by dividing patients into two groups: those who had education levels beyond high school and those who did not.
Conclusions

In severe COPD patients, low income is independently associated with EC. Our results may be of importance to fully assess patients with severe COPD addressing social determinants of health.

Authors' note

Complete list of the NETT Research Group members: Members of the NETT Research Group are as follows: Office of the Chair of the Steering Committee, University of Pennsylvania, Philadelphia, PA: Alfred P. Fishman, M.D. (Chair); Betsy Ann Bozzarello; Ameena Al-Amin. Clinical centers: Baylor College of Medicine, Houston, TX: Marcia Katz, M.D. (Principal Investigator); Carolyn Wheeler, R.N., B.S.N. (Principal Clinic Coordinator); Elaine Baker, R.R.T., R.P.F.T.; Peter Barnard, PhD, R.P.F.T.; Phil Cagle, M.D.; James Carter, M.D.; Sophia Chatziioannou, M.D.; Karla Conejo-Gonzales; Kimberly Dubose, R.R.T.; John Haddad, M.D.; David Hicks, R.R.T., R.P.F.T.; Neal Kleiman, M.D.; Mary Milburn-Barnes, C.R.T.T.; Chinh Nguyen, R.P.F.T.; Michael Reardon, M.D.; Joseph Reeves-Viets, M.D.; Steven Sax, M.D.; Amir Sharafkhaneh, M.D.; Owen Wilson, PhD; Christine Young, P.T.; Rafael Espada, M.D. (Principal Investigator 1996–2002); Rose Butanda (1999–2001); Minnie Ellisor (2002); Pamela Fox, M.D. (1999–2001); Katherine Hale, M.D. (1998–2000); Everett Hood, R.P.F.T. (1998–2000); Amy Jahn (1998–2000); Satish Jhingran, M.D. (1998–2001); Karen King, R.P.F.T. (1998–1999); Charles Miller III, PhD (1996–1999); Imran Nizami, M.D. (Co-Principal Investigator, 2000–2001); Todd Officer (1998–2000); Jeannie Ricketts (1998–2000); Joe Rodarte, M.D. (Co-Principal Investigator 1996–2000); Robert Teague, M.D. (Co-Principal Investigator 1999–2000); Kedren Williams (1998–1999); Brigham and Women’s Hospital, Boston, MA: John Reilly, M.D. (Principal Investigator); David Sugarbaker, M.D. (Co-Principal Investigator); Carol Fanning, R.R.T. (Principal Clinic Coordinator); Simon Body, M.D.; Sabine Duffy, M.D.; Vladimir Formanek, M.D.; Anne Fuhlbrügge, M.D.; Philip Hartigan, M.D.; Sarah Hoooper, E.P.; Andetta Hunsaker, M.D.; Francine Jacobson, M.D.; Marilyn Moy, M.D.; Susan Peterson, R.R.T.; Roger Russell, M.D.; Diane Saunders; Scott Swanson, M.D. (Co-Principal Investigator, 1996–2001). Cedars-Sinai Medical Center, Los Angeles, CA: Rob McKenna, M.D. (Principal Investigator); Zab Mohsenifar, M.D. (Co-Principal Investigator); Carol Geaga, R.N. (Principal Clinic Coordinator); Mannohann Birring, M.D.; Susan Clark, R.N., M.N.; Jennifer Cutler, M.D.; Robert Frantz, M.D.; Peter Julien, M.D.; Michael Lewis, M.D.; Jennifer Minkoff-Rau, M.S.W.; Valentina Yegyan, B.S., C.P.F.T.; Milton Joyner, B.A. (1996–2002). Cleveland Clinic Foundation, Cleveland, OH: Malcolm DeCamp, M.D. (Principal Investigator); James Stoller, M.D. (Co-Principal Investigator); Yvonne Meli, R.N., M.D. (Co-Principal Clinic Coordinator); John Apostolakis, M.D.; Darryl Atwell, M.D.; Jeffrey Chapman, M.D.; Pierre Devilliers, M.D.; Raed Dweik, M.D.; Erik Kraenzler, M.D.; Rosemary Lann, L.I.S.W.; Nancy Kurokawa, R.R.T., R.P.F.T.; Scott Marlow, R.R.T.; Kevin McCarthy, R.C.P.T.; Priscilla McCreight, R.R.T., C.P.F.T.; Atul Mehta, M.D., M.S.; Moulay Meziane, M.D.; Omar Minai, M.D.; Mindi Steiger, R.R.T.; Kenneth White, R.P.F.T.; Janet Maurer, M.D. (Principal Investigator, 1996–2001); Terri Durr, R.N. (2000–2001); Charles Hearn, D.O. (1998–2001); Susan Lubell, P.A.-C. (1999–2000); Peter O’Donovan, M.D. (1998–2003); Robert Schilz, D.O. (1998–2002). Columbia University, New York, NY in

Table 3. Income as a determinant of watts in CPET, adjusted for age, sex, Post FEV1% predicted, mMRC, loneliness, married status, smoking pack years and education beyond high school.

| Variables                        | DF | Parameter estimates | Standard error | t Value | Pr > |t|   |
|----------------------------------|----|---------------------|----------------|---------|------|-----|
| Intercept                        | 1  | 48.24               | 5.99           | 8.06    | <0.0001 |
| Married                          | 1  | 1.79                | 1.16           | 1.55    | 0.1222 |
| Lonely or isolated               | 1  | -0.48               | 1.85           | -0.26   | 0.7957 |
| Income < US$30,000               | 1  | -2.27               | 1.11           | -2.04   | 0.0419 |
| Age                              | 1  | -0.77               | 0.08           | -9.14   | <0.001 |
| Sex, male                        | 1  | 22.14               | 1.12           | 19.83   | <0.001 |
| Post BD FEV1% predicted          | 1  | 1.36                | 0.07           | 18.60   | <0.0001 |
| mMRC                             | 1  | -2.88               | 0.54           | -5.34   | <0.0001 |
| Education beyond high school     | 1  | 2.14                | 1.05           | 2.04    | 0.0417 |
| Smoking pack years               | 1  | 0.01                | 0.02           | 0.47    | 0.6416 |

DF: degrees of freedom; Pr > |t|: t-test significance level; Post BD FEV1% pred: postbronchodilator forced expiratory volume in 1 second; mMRC: Modified medical research council scale. Every value in italics <0.05 denotes significance (standard practice).
aLoneliness and isolation was measured by asking subjects “Do you feel lonely or socially isolated now or in the last 3 days?”. An answer was either “yes” or “no”.bEducation was determined by dividing patients into two groups: those who had education levels beyond high school and those who did not.
Deborah Nowakowski; Kapreena Owens; Shangqian Qi, Levine; Hope Livingston; Jill Meinert; Jennifer Meyers; Judith Harle; Rosetta Jackson; Shing Lee, Sc.M.; Charlene Vera Edmonds; Gregory L. Foster, M.A.; Julie Fuller; Colvin, M.P.H.; John Dodge; Michele Donithan, M.H.S.; Blackford, Sc.M.; Karen Collins; Betty Collison; Ryan PhD (Co-Principal Investigator); Patricia McDowell; Donald Oxorn, M.D.; Liz Roessler; Geral d Ayres; Michael Donahoe, M.D.; Lisa Louis Grant, M.S.; Carl Fuhrman, M.D.; Robert Hoffman, M.D.; Joan Lacomis, M.D.; Joan Sexton; William Slivka; Diane Strollo, M.D.; Erin Sullivan, M.D.; Tomeka Simon; Catherine Wrona, R.N., B.S.N.; Gerene Bauldoff, R.N., M.S.N. (1997–2000); Manuel Brown, M.D. (1997–2002); Elizabeth George, R.N., M.S.N. (Principal Clinic Coordinator); Colleen Witt, M.S. (Principal Clinic Coordinator); Gerald Ayres; Michael Donahoe, M.D.; Carl Fuhrman, M.D.; Robert Hoffman, M.D.; Joan Lacomis, M.D.; Joan Sexton; William Slivka; Diane Strollo, M.D.; Erin Sullivan, M.D.; Tomeka Simon; Catherine Wrona, R.N., B.S.N.; Gerene Bauldoff, R.N., M.S.N. (1997–2000); Manuel Brown, M.D. (1997–2002); Elizabeth George, R.N., M.S.N. (Principal Clinic Coordinator) 1997–2001); Robert Keenan, M.D. (Co-Principal Investigator); James Luketich, M.D. (Co-Principal Investigator); Colleen Witt, M.S. (Principal Clinic Coordinator); Gerald Ayres; Michael Donahoe, M.D.; Carl Fuhrman, M.D.; Robert Hoffman, M.D.; Joan Lacomis, M.D.; Joan Sexton; William Slivka; Diane Strollo, M.D.; Erin Sullivan, M.D.; Tomeka Simon; Catherine Wrona, R.N., B.S.N.; Gerene Bauldoff, R.N., M.S.N. (1997–2000); Manuel Brown, M.D. (1997–2002); Elizabeth George, R.N., M.S.N. (Principal Clinic Coordinator) 1997–2001); Robert Keenan, M.D. (Co-Principal Investigator) 1997–2000); Theodore Kopp, M.S. (1997–1999); Laurie Silflies (1997–2001). University of Washington, Seattle, WA: Joshua Benditt, M.D. (Principal Investigator); Douglas Wood, M.D. (Co-Principal Investigator); Margaret Snyder, M.N. (Principal Clinic Coordinator); Kimberly Anable; Nancy Battaglia; Louie Boitano; Andrew Bowdle, M.D.; Leighton Chan, M.D.; Cindy Chwalik; Bruce Culver, M.D.; Thurman Gillespy, M.D.; David Godwin, M.D.; Jeanne Hoffman; Andra Ibrahim, M.D.; Diane Lockhart; Stephen Marglin, M.D.; Kenneth Martay, M.D.; Patricia McDowell; Donald Oxorn, M.D.; Liz Roessler; Michelle Toshima; Susan Golden (1998–2000). Other participants: Agency for Healthcare Research and Quality, Rockville, MD: Lynn Bosco, M.D., M.P.H.; Yen-Pin Chiang, PhD; Carolyn Clancy, M.D.; Harry Handelsman, D.O. Centers for Medicare and Medicaid Services, Baltimore, M.D.: Steven M Berkowitz, PhD; Tanisha Carino, PhD; Joe Chin, M.D.; JoAnna Baldwin; Karen McVearry; Anthony Norris; Sarah Shirey; Claudette Sikora; Steven Sheingold, PhD (1997–2004). Coordinating Center, The Johns Hopkins University, Baltimore, MD: Steven Piantsadosi, M.D., PhD (Principal Investigator); James Tomac, PhD (Co-Principal Investigator); Patricia Belt; Amanda Blackford, Sc.M.; Karen Collins; Betty Collison; Ryan Colvin, M.P.H.; John Dodge; Michele Donithan, M.H.S.; Vera Edmonds; Gregory L. Foster, M.A.; Julie Fuller; Judith Harle; Rosetta Jackson; Shing Lee, Sc.M.; Charlene Levine; Hope Livingston; Jill Meinert; Jennifer Meyers; Deborah Nowakowski; Kapreana Owens; Shangqian Qi, M.D.; Michael Smith; Brett Simon, M.D.; Paul Smith; Alice Sternberg, Sc.M.; Mark Van Natta, M.H.S.; Laura Wilson, Sc.M.; Robert Wise, M.D. Cost Effectiveness Subcommittee: Robert M. Kaplan, PhD (Chair); J. Sanford Schwartz, M.D. (Co-Chair); Yen-Pin Chiang, PhD; Marianne C. Fahn, PhD; A. Mark Fendrick, M.D.; Alan J. Moskowitz, M.D.; Dev Pathak, PhD; Scott Ramsey, M.D., PhD; Steven Sheingold, PhD; A. Laurie Shroyer, PhD; Judith Wagner, PhD; Roger Yusan, M.D. Cost Effectiveness Data Center, Fred Hutchinson Cancer Research Center, Seattle, WA: Scott Ramsey, M.D., PhD (Principal Investigator); Ruth Etzioni, PhD; Sean Sullivan, PhD; Douglas Wood, M.D.; Thomas Schroeder, M.A.; Karma Kreizenbeck; Kristin Berry, M.S.; Nadia Howlader, M.S. CT Scan Image Storage and Analysis Center, University of Iowa, Iowa City, IA: Eric Hoffman, PhD (Principal Investigator); Janice Cook-Granroth, B.S.; Angela Delsing, R.T.; Junfeng Guo, PhD; Geoffrey McLennan, M.D.; Brian Mullan, M.D.; Chris Piker, B.S.; Joseph Reinhardt, PhD; Blake Wood; Jered Sieren, R.T.R.; William Stanford, M.D. Data and Safety Monitoring Board: John A. Waldhausen, M.D. (Chair); Gordon Bernard, M.D.; David DeMets, PhD; Mark Ferguson, M.D.; Eddie Hoover, M.D.; Robert Levine, M.D.; Donald Mahler, M.D.; A. John McSweeney, PhD; Jeanine Wiener-Kronish, M.D.; O. Dale Williams, PhD; Magdy Younes, M.D. Marketing Center, Temple University, Philadelphia, PA: Gerard Criner, M.D. (Principal Investigator); Charles Soltoff, M.B.A. Project Office, National Heart, Lung, and Blood Institute, Bethesda, MD: Gail Weinmann, M.D. (Project Officer); Joanne Deshler (Contracting Officer); Dean Follmann, PhD; James Kiley, PhD; Margaret Wu, PhD (1996–2001).

Declaration of competing interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The financial support of this work from the NIH Clinical Center (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N0). Dr Benzo is funded by grant K24 HL138150 from the National Institutes of Health, USA.

ORCID iD

Roberto Benzo https://orcid.org/0000-0001-6800-8234

References

1. ZuWallack RL, Haggerty MC, and Jones P. Clinically meaningful outcomes in patients with chronic
obstructive pulmonary disease. *Am J Med* 2004; 117(suppl 12A): 49S–59S.
2. Solway S, Brooks D, Lacasse Y, et al. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiopulmonary domain. *Chest* 2001; 119(1): 256–270.
3. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. *Eur Respir J* 2008;31(2): 416–469.
4. Durheim MT, Smith PJ, Babyak MA, et al. Six-minute-walk distance and accelerometry predict outcomes in chronic obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group. *Ann Am Thorac Soc* 2015; 12(3): 349–356.
5. Pinto-Plata VM, Cote C, Cabral H, et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. *Eur Respir J* 2004; 23(1): 28–33.
6. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 2002; 166(1): 111–117.
7. Salzman SH. The 6-min walk test: clinical and research role, technique, coding, and reimbursement. *Chest* 2009; 135(5): 1345–1352.
8. Foglio K, Carone M, Pagani M, et al. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. *Respir Med* 2000; 94(3): 256–263.
9. Bak-Drabik K and Ziora D. The impact of socioeconomic status on the quality of life in patients with chronic obstructive pulmonary disease. *Pneumonol Allergol Pol* 2010; 78(1): 3–13.
10. Gimeno-Santos E, Frei A, Steurer-Stey C, et al. Determinants and outcomes of physical activity in patients with COPD: a systematic review. *Thorax* 2014; 69(8): 731–739.
11. Cho KH, Nam CM, Lee EJ, et al. Effects of individual and neighborhood socioeconomic status on the risk of all-cause mortality in chronic obstructive pulmonary disease: a nationwide population-based cohort study, 2002-2013. *Respir Med* 2016; 114: 9–17.
12. Eisner MD, Blanc PD, Omachi TA, et al. Socioeconomic status, race and COPD health outcomes. *J Epidemiol Community Health* 2011; 65(1): 26–34.
13. Fishman A, Martinez F, Nauheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *N Engl J Med* 2003; 348(21): 2059–2073.
14. Rationale and design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. The National Emphysema Treatment Trial Research Group. *Chest* 1999; 116(6): 1750–1761.
15. U.S. Census Bureau. *Current population reports, P60-213, Money income in the United States: 2000.* Washington, DC: U.S. Government Printing Office, 2001.
16. Pew Research Center analysis of the 2000 decennial census and 2014 American Community Survey (IPUMS). *America’s shrinking middle class: A close look at changes within metropolitan areas.* Washington, DC: Pew Research Center, 2016.
17. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2003; 167(2): 211–277.
18. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005; 26(2): 319–338.
19. Miller MR, Crapo R, Hankinson J, et al. General considerations for lung function testing. *Eur Respir J* 2005; 26(1): 153–161.
20. Kaplan RM, Anderson JP, Wu AW, et al. The quality of well-being scale. applications in AIDS, cystic fibrosis, and arthritis. *Med Care* 1989; 27(suppl 3): S27–S43.
21. Thorpe O, Johnston K, and Kumar S. Barriers and enablers to physical activity participation in patients with COPD: a systematic review. *J Cardiopulm Rehabil Prev* 2012; 32(6): 359–369.
22. Amorim PB, Stelmach R, Carvalho CR, et al. Barriers associated with reduced physical activity in COPD patients. *J Bras Pneumol* 2014; 40(5): 504–512.
23. Steiner MC, Lowe D, Beckford K, et al. Socioeconomic deprivation and the outcome of pulmonary rehabilitation in England and Wales. *Thorax* 2017; 72(6): 530–537.